Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASC40 in moderate to severe acne vulgaris
NCT05104125Phase 2Completed
- Sponsor
- Ascletis Pharma Inc.
- Start
- Jan 2022
- Primary completion
- Apr 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of denifanstat in acne vulgaris (4 arms), sponsored by Ascletis Pharma Inc. Primary endpoints: Percentage change of total lesion count from baseline at 12 weeks and Proportion of subjects with IGA grade decreased by >= 2 grades at 12 weeks. Started Jan 2022; status: completed.
02
Drugs
denifanstat
03
Conditions
acne vulgaris
Beyond the preview
Go deeper on NCT05104125.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05104125.